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Protein Tyrosine Kinase 6 Regulates UVB-Induced
Signaling and Tumorigenesis in Mouse Skin
Michael I. Chastkofsky1,2, Wenjun Bie1, Susan M. Ball-Kell3, Yu-Ying He4 and Angela L. Tyner1
Protein tyrosine kinase 6 (PTK6, also called BRK) is an intracellular tyrosine kinase expressed in the epithelial
linings of the gastrointestinal tract and the skin, where it is expressed in nondividing differentiated cells. We
found that PTK6 expression increases in the epidermis following UVB treatment. To evaluate the roles of PTK6 in
the skin following UVB-induced damage, we exposed back skin of Ptk6 +/+ and Ptk6 − /− SENCAR mice to
incremental doses of UVB for 30 weeks. Wild-type mice were more sensitive to UVB and exhibited increased
inﬂammation and greater activation of signal transducer and activator of transcription-3 (STAT3) than Ptk6− /−
mice. Disruption of Ptk6 did not have an impact on proliferation, although PTK6 was expressed and activated in
basal epithelial cells in wild-type mice following UVB treatment. However, wild-type mice exhibited shortened
tumor latency and increased tumor load compared with Ptk6− /− mice, and STAT3 activation was increased in
these tumors. PTK6 activation was detected in UVB-induced tumors, and this correlated with increased activating
phosphorylation of focal adhesion kinase (FAK) and breast cancer anti-estrogen resistance 1 (BCAR1). Activation
of PTK6 was also detected in human squamous cell carcinomas of the skin. Although PTK6 has roles in normal
differentiation, it also contributes to UVB-induced injury and tumorigenesis in vivo.
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INTRODUCTION
Protein tyrosine kinase 6 (PTK6) is an intracellular tyrosine
kinase that regulates growth and differentiation, as well as
the response to DNA damage in epithelia (reviewed in Brauer
and Tyner, 2010). PTK6 was originally cloned from human
melanocytes (Lee et al., 1993), human breast tumors (Mitchell
et al., 1994), and the mouse intestine (Siyanova et al., 1994). It
is most highly expressed in the gastrointestinal tract and the
skin, where its expression is localized to differentiated epithelial
cells (Vasioukhin et al., 1995). PTK6 is also expressed in the
prostate (Derry et al., 2003; Zheng et al., 2013a) and at low
levels in human breast tissue (Peng et al., 2014).
PTK6 is developmentally regulated and is ﬁrst expressed in
the skin at mouse embryonic day 15.5, when the skin
becomes stratiﬁed (Vasioukhin et al., 1995). PTK6 is expres-
sed in suprabasal layers of the adult mouse and human skin
(Vasioukhin et al., 1995; Wang et al., 2005). Calcium-
induced differentiation in embryonic mouse keratinocytes
resulted in increased PTK6 activity and expression of the skin
differentiation marker ﬁlaggrin (Vasioukhin and Tyner, 1997).
In oral squamous cell carcinomas (SCCs), PTK6 expression
was reduced, and active PTK6 was excluded from the nucleus
(Petro et al., 2004).
Analysis of Ptk6-null mice revealed delayed differentiation
of intestinal epithelial cells (Haegebarth et al., 2006) and
increased villus length compared with wild-type intestine.
PTK6 expression was induced in intestinal crypt cells in
response to DNA damage, and Ptk6-null mice displayed
resistance to DNA damage–induced apoptosis in the intestine
(Haegebarth et al., 2009; Gierut et al., 2011). When treated
with the carcinogen azoxymethane, Ptk6-null mice were
resistant to colon tumor formation compared with wild-type
mice (Gierut et al., 2011). Activating phosphorylation of
signal transducer and activator of transcription-3 (STAT3), a
substrate of PTK6 (Liu et al., 2006), was impaired in PTK6-null
mice following administration of azoxymethane (Gierut et al.,
2011). STAT3 has important roles in normal skin and skin
carcinogenesis (reviewed in Kim et al., 2007; Sano et al.,
2008; Macias et al., 2013). It regulates proliferation and
survival of keratinocytes following exposure to UVB, and it is
activated in SCCs induced by UVB (Sano et al., 2005).
Additional PTK6 substrates include focal adhesion kinase
(FAK) (Zheng et al., 2013a) and the adaptor protein breast
cancer anti-estrogen resistance 1 (BCAR1), also commonly
called p130CAS (Zheng et al., 2012). FAK and BCAR1
regulate cell adhesion, migration, and proliferation and have
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important roles in cancer (Cabodi et al., 2010; Sulzmaier
et al., 2014). Membrane localization of active PTK6
phosphorylated on tyrosine residue 342 (PY342) has been
shown to promote phosphorylation of both FAK and BCAR1
and the epithelial–mesenchymal transition in prostate cancer
cells (Zheng and Tyner, 2013).
To date, no in vivo studies have explored the signiﬁcance of
PTK6 expression in normal skin and its roles in the UVR-
induced DNA damage response and skin cancer. Using a
Ptk6-null mouse model in the SENCAR (SENsitive to
CARcinogenesis) background, we examined the impact of
loss of PTK6 on skin development and examined how
disruption of Ptk6 affects UVB-induced tumor formation in
mouse skin. Here we demonstrate that PTK6 is activated in
both human and mouse skin tumors, and it positively
regulates STAT3, FAK, and BCAR1 and contributes to UVB-
induced tumor formation in vivo.
RESULTS
Disruption of Ptk6 impairs UVB-induced tumorigenesis
PTK6 was shown to promote tumorigenesis in the mouse
colon following carcinogen-induced DNA damage (Gierut
et al., 2011). To examine the roles of PTK6 in UVB-induced
carcinogenesis, we backcrossed Ptk6− /− C57BL/6 mice into
the SENCAR mouse strain that was previously shown to be
sensitive to UVR-induced carcinogenesis (Strickland, 1982,
1986; Strickland and Swartz, 1987) and used to examine
differentiation-promoting roles for PTK6 (Sik) in keratinocytes
(Vasioukhin and Tyner, 1997). In order to determine the effect
of PTK6 on UVB-induced tumorigenesis, shaved 8-week-old
wild-type and Ptk6− /− SENCAR mice were treated with
incremental doses of UVB three times each week for a total of
30 weeks. After an additional latency period of 13 weeks,
mice were killed at 51 weeks of age. Wild-type mice began
developing tumors at 28 weeks of age, and all of them had
developed tumors by 36 weeks of age (Figure 1a). In contrast,
Ptk6− /− mice did not begin to develop tumors until
32 weeks of age, and only half developed tumors. None
of the control untreated wild-type or Ptk6− /− mice, which
were routinely shaved, developed tumors. Wild-type
mice developed a greater tumor load than Ptk6− /− mice,
averaging 3.8 tumors per mouse, whereas Ptk6− /− mice
developed an average of 1.5 tumors per mouse (Figure 1b);
representative wild-type and Ptk6− /− animals are shown at
later time points (Figure 1c).
UVB exposure leads to increased PTK6 expression and
activation in the skin
Increased sensitivity of wild-type mice to UVB was observed a
few weeks after beginning the UVB tumor induction protocol
(Figure 2a). Wild-type mice experienced a moderate-to-severe
inﬂammatory reaction to UVB that was visible within a
week after the ﬁrst dose was administered. In comparison,
Ptk6− /− mouse skin exhibited a mild inﬂammatory reaction
with only a slight reddening of the skin that faded by the
second week. We examined sections of the skin and detected
multifocal degeneration/necrosis of the upper epidermal
layers in wild-type mice, sometimes with complete loss of
stratum corneum. Neutrophilic migration and microabscess
formation could be found in these regions with or without the
intact stratum corneum in the wild-type animals (Figure 2b).
Little apoptosis was detected at this time point in wild-type
and Ptk6− /− mice by the TUNEL assay (data not shown).
The inﬂammatory reaction faded as the skin became
hyperplastic and adapted to the stress of UVB treatment,
completely healing after 4 weeks in the wild-type animals.
To determine the impact of short-term UVB treatment on
PTK6 expression and activation, wild-type SENCAR mice
were treated with 5 doses of UVB over 10 days. PTK6
expression and activation were examined by immunoblotting
and immunoﬂuorescence. PTK6 protein expression levels
increased up to 3-fold (Figure 2c and d), but immunoblotting
was not sensitive enough to detect activation of PTK6 PY342.
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Figure 1. Ptk6− /− mice are resistant to UVB-induced tumorigenesis.
(a) Kinetics of UVB-induced tumor development in wild-type and Ptk6− /−
mouse skin. Ptk6+/+ mice developed tumors sooner than Ptk6− /− mice.
All Ptk6+/+ mice developed tumors, whereas only half of Ptk6− /− mice did.
(b) The average (Avg.) number of tumors that developed in wild-type and
Ptk6− /− mice is shown. (c) Tumor formation in representative wild-type
and Ptk6− /− animals is shown at the indicated time points, including one of
the tumor-positive Ptk6− /− mice at 42 weeks. PTK6, protein tyrosine kinase.
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We observed hyperplasia of the skin and using immuno-
ﬂuorescence PTK6 was found throughout the wild-type skin,
with highest signals in the suprabasal layers (Figure 2e). Active
PTK6 PY342 was detected in a subset of cells within the basal
layer. We validated the antibody against active PTK6 PY342
by using it against Ptk6− /− tissues and did not detect a
speciﬁc signal (control, lower right panel).
Disruption of Ptk6 impairs STAT3 activation
STAT3 is an important regulator of inﬂammation (reviewed in
Yu et al., 2009) and a direct substrate of PTK6. PTK6 promotes
STAT3 activation by phosphorylating it on tyrosine residue
705. To examine activation of STAT3 following short-term
UVB treatment, total skin lysates were probed for STAT3
activation using an antibody speciﬁc for active STAT3 PY705.
STAT3 activity was not signiﬁcantly different between wild-
type and PTK6-null untreated skin (Figure 3a). However, after
short-term UVB treatment, STAT3 was activated in wild-type
skin but not in Ptk6− /− skin. Phosphorylation of STAT3
was quantitated, and differences in activation between
wild-type and Ptk6− /− mice were statistically signiﬁcant
(Figure 3b). When analyzed using immunoﬂuorescence,
active STAT3 was detected in a greater number of nuclei in
Ptk6+/+ skin than in Ptk6− /− skin at 10 days into the UVB
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Figure 2. Increased inﬂammation and protein tyrosine kinase 6 (PTK6) expression are detected in wild-type mice after UVB treatment. (a) Increased and
prolonged inﬂammation was detected in wild-type mice compared with Ptk6− /− mice after short-term exposure to UVB. Ptk6+/+ mice (left panels) developed
erythema and an inﬂammatory reaction on the lower dorsal skin within a week after beginning UVB treatments. Mice were treated with UVB three times a week.
Scale bar=1 cm. (b) Increased degeneration and necrosis of the upper epidermal layers with neutrophilic migration and microabscess formation was detected in
wild-type mice when compared with Ptk6− /− skin at 10 days after initiation of short-term UVB treatment. Representative hematoxylin and eosin (H&E)–stained
sections are shown. Scale bar=100 mm. (c) PTK6 expression is induced by UVB treatment in mouse skin. Lysates of adult (8 weeks old) mouse skin after short-
term UVB were prepared and analyzed by immunoblotting. Each lane represents a sample from a different mouse. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a loading control. (d) The increase in PTK6 expression after UVB treatment (c) was quantiﬁed using ImageJ (Rasband, 2011). The intensity
of PTK6 signal was normalized to intensity of the GAPDH loading control and averaged across all samples. *P= 0.025. (e) Total PTK6 and active PTK6 Y342
expression was examined by immunoﬂuorescence in untreated and UVB-treated skin. Keratin-14 is expressed throughout the hyperplastic skin after UVB
treatment. Controls included staining with IgG and staining of UVB-treated Ptk6− /− skin with the antibody against PTK6 phosphorylated on tyrosine residue 342
(PY342). No speciﬁc signal for PY342 was detected in Ptk6− /− mice. Scale bar= 20 μm.
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treatments (Figure 3c). At the end point of the long-term study,
we also observed an increase in STAT3 PY705 in epidermal
cell nuclei of hyperplastic wild-type skin compared with
Ptk6− /− skin (Figure 3d).
PTK6 is activated in UVB-induced tumors but does not coincide
with proliferation
UVB-treated skin and tumors from control wild-type and
Ptk6− /− mice were examined by a veterinary pathologist
(SM Ball-Kell). Tumors types ranged from well-differentiated
SCCs to spindle cell squamous cell tumors (Figure 4b, lower
right panel). In both wild-type and Ptk6− /− mice, moderate
hyperkeratosis and acanthosis of the epidermis with irregular
formation of rete ridges was observed. At the end point, which
occurred either at the termination of the experiment when
the mice were ∼ 80 weeks of age or when mice were killed
earlier at a humane end point, active PY342 PTK6 was
detected in the UVB-irradiated skin. PTK6 PY342 was
localized to different intracellular regions within the same
section in some samples. For example, although active PTK6
was detected at the membrane in the basal layer of the
hyperplastic epidermis, it was in the cytoplasm or nucleus of
neoplastic cells in the spindle cell squamous cell tumors
(Figure 4a and b). Hyperplasia as well as necroulcerative
dermatitis and actinic keratosis were observed in wild-type
mice. Total PTK6 was generally more highly expressed in the
keratin-10-positive suprabasal layers of the epidermis,
whereas active PTK6 PY342 was localized at the membrane
in the more basal keratin-14-positive region of the tumors
(Figure 4b). Spindle cell squamous cell tumors contained cells
in the dermis that expressed both total PTK6 and PTK6 PY342
(Figure 4b). Immunohistochemistry for keratin-10 and keratin-
14 expression conﬁrmed the epithelial origin of the tumor
cells within the dermis (Figure 4b).
To determine the roles of PTK6 in regulating proliferation at
the end point of the experiment, BrdU incorporation was
examined in hyperplastic skin, spindle cell squamous cell
tumors (Figure 4c), and SCCs from UVB-treated Ptk6+/+ and
Ptk6− /− mice. No signiﬁcant differences in the numbers of
BrdU incorporating S-phase cells were detected in any of
the samples. Costaining for active PTK6 PY342 and BrdU
incorporation indicated that cells with active PTK6 at the
membrane are distinct from the BrdU incorporating cells,
suggesting that the active PTK6 does not directly promote
S-phase progression at the time points examined. We also did
not detect a signiﬁcant difference in BrdU incorporation in
younger Ptk6+/+ and Ptk6− /− mouse skin after 10 days of
UVB treatment (not shown).
PTK6 regulates phosphorylation of FAK and BCAR1 in
UVB-treated skin
PTK6-mediated tyrosine phosphorylation of FAK has pre-
viously been shown to inhibit anoikis (Zheng et al., 2013a).
PTK6 regulates phosphorylation of FAK at several tyrosine
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Figure 3. Protein tyrosine kinase 6 (PTK6) promotes signal transducer and activator of transcription-3 (STAT3) activation after UVB treatment. (a) Increased
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lysate from an individual mouse, and a minimum of three mice were examined per treatment. (b) Changes in STAT3 activation (PY705) after UVB treatment were
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Ptk6+/+ and Ptk6− /− UVB-treated skin (**P=0.009). (c) Increased nuclear localization of STAT3 PY705 was detected by immunoﬂuorescence in wild-type
mouse skin (10-day UVB treatment). (d) Increased nuclear localization of STAT3 PY705 was detected by immunoﬂuorescence in wild-type mouse skin following
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residues, including Y576/Y577 and Y925, that regulate
activation and GRB2 binding, respectively (Sulzmaier et al.,
2014). To examine PTK6-mediated regulation of FAK, we
stained sections of the skin with antibodies speciﬁc for FAK
phosphorylated on Y576/Y577 and Y925. No differences
in phosphorylation of Y576/577 or Y925 were observed
between wild-type and Ptk6− /− untreated skin (Figure 5a).
After short-term (10 days) UVB treatment, some wild-type
epidermal cells contained FAK phosphorylated at both Y576/
Y577 and at Y925, whereas no speciﬁc signals could be
detected in Ptk6− /− epidermis (Figure 5b). At the end point,
FAK phosphorylation at Y576/Y577 and Y925 was detected
throughout the Ptk6+/+ hyperplastic epidermis, with striking
membrane localization of PY925 in the upper layers. The
pattern of FAK phosphorylation was less intense and much
less striking in the Ptk6− /− skin (Figure 5c).
We previously showed that PTK6 promotes phosphoryla-
tion of tyrosine residue 165 in BCAR1 (p130CAS) (Zheng
et al., 2012). In untreated skin, cells strongly positive for
BCAR1 phosphorylated on tyrosine residue 165 (Y165) were
detected only in Ptk6+/+ skin but not in Ptk6− /− skin
(Figure 5d, arrows). UVB irradiation promotes Y165 phos-
phorylation of BCAR1 in both genotypes, but the BCAR1
PY165 signal is stronger in Ptk6+/+ skin than in Ptk6− /−
skin (Figure 5e). BCAR1 is strongly phosphorylated at Y165 in
the end point Ptk6+/+ skin, particularly in the suprabasal
layers of the epidermis, but is not highly phosphorylated in
Ptk6− /− skin (Figure 5f).
PTK6 is activated in human cutaneous SCCs
In order to explore the possible clinical signiﬁcance of our
mouse data, we examined PTK6 expression in a set of 34
human biopsy sections that included normal skin and SCCs.
Sections were double stained for total and active PTK6
(PY342), and a section from the same block was hematoxylin
and eosin stained (Figure 6). In normal human skin, PTK6
expression was detected in the suprabasal layer of the
epidermis, with minimal expression in the basal layer
(Figure 6a), as reported previously (Vasioukhin et al., 1995;
Wang et al., 2005). Signiﬁcant activating phosphorylation of
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PTK6 (PY342) was not detected in normal human skin.
However, in SCC, PTK6 is activated and phosphorylated
in some epidermal cells, particularly those located at the
borders of the epidermis/dermis (SCC1A and 1B). In another
SSC sample (SCC 2), most active PTK6 PY342 was found
adjacent to the keratinized surface area and next to a
blood vessel (Figure 6a). These data show that high PTK6
expression levels do not always correlate with PTK6 activa-
tion. In addition, activation of PTK6 is regulated by environ-
mental cues and is not uniformly detected in PTK6-positive
tissue.
Transcriptome proﬁling of human cutaneous SCC at
different stages of progression was recently performed by
Lambert et al. (2014) using laser capture microdissection
and microarray analysis. By analyzing PTK6 mRNA levels in
the data sets of Lambert et al. (2014), we found that Ptk6
transcript levels were reduced in SCCs compared with the
precancerous actinic keratosis (Figure 6b). In addition, there
was a signiﬁcant difference in PTK6 transcript levels between
well-differentiated SCCs and poorly differentiated SCCs.
Although PTK6 protein expression levels did not appear
reduced in SCCs examined by immunoﬂuorescence, this is
not a highly quantitative technique. It is also possible that
posttranscriptional mechanisms are important for the regula-
tion of PTK6 protein levels.
DISCUSSION
PTK6 belongs to a small family of intracellular tyrosine
kinases that includes FRK and SRMS and is evolutionarily
related to the SRC family (Serfas and Tyner, 2003; D'Aniello
et al., 2008). Although PTK6 family kinases share structural
similarity with SRC family kinases, PTK6 family members lack
an amino terminal SH4 domain that promotes lipid modiﬁca-
tion and membrane targeting. Nevertheless, membrane
association of active endogenous PTK6 has been detected
in mouse and human prostate (Zheng et al., 2013a; Zheng
and Tyner, 2013) and mammary gland (Peng et al., 2013,
2014) tumors. A variety of data suggest that the intracellular
localization and activation of PTK6 has profound effects on its
activities. PTK6 can be detected in the nuclei of normal
differentiated glands of the human prostate, but nuclear
localization is lost in prostate cancer (Derry et al., 2003).
Reintroduction of ectopic PTK6 into the nuclei of prostate
cancer cells is growth inhibiting (Brauer et al., 2010). In
studies where PTK6 was targeted to the plasma membrane in
cell lines by the addition of a SH4 domain, membrane
association of active PTK6 was sufﬁcient to transform mouse
embryonic ﬁbroblasts (Zheng et al., 2013a), promote the
epithelial–mesenchymal transition, and contribute to human
xenograft prostate tumor growth in vivo (Zheng et al., 2013b).
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patient sample, SCC1A and SCC1B, are shown, whereas SCC 2 is from a different patient. Scale bars=20 μm. Eighteen SCC samples were analyzed. Fluorescent
signals over the red blood cells is the background that can also be detected with control IgG (not shown). (b) Transcriptome analysis of RNA expression in SCC
(Lambert et al., 2014) revealed that PTK6 mRNA expression decreases in SCCs compared with actinic keratosis (*P= 0.008). The drop in PTK6 mRNA expression
in SCCs corresponds with decreased differentiation (**P= 0.031).
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Here, we demonstrate that active PTK6 is associated with
the plasma membrane in mouse skin tumors induced by UVB
and in human cutaneous SCCs. As PTK6 is expressed in
normal differentiated nondividing epithelial cells in the
gastrointestinal tract and the skin (Vasioukhin et al., 1995),
and has been shown to promote differentiation in small
intestine (Haegebarth et al., 2006) and cultured keratinocytes
(Vasioukhin and Tyner, 1997; Wang et al., 2005), we initially
proposed that PTK6 might have tumor suppressor functions
in the gut and the skin. However, we found that Ptk6 impairs
cutaneous tumor growth in the UVB skin model, demons-
trating that PTK6 signaling is contributing to tumor
development in vivo. These data are consistent with those
obtained with intestinal tissues where PTK6 is also normally
expressed in the nondividing, differentiated epithelial cells.
Disruption of the Ptk6 gene led to signiﬁcantly reduced tumor
formation in mice treated with the colon carcinogen
azoxymethane and impaired activation of STAT3 (Gierut
et al., 2011).
In the colon, disruption of Ptk6 impaired activation of
STAT3, a transcription factor that promotes epithelial tumor
initiation and progression (Gierut et al., 2011). In this study,
we observed increased activating tyrosine phosphorylation
and nuclear localization of STAT3 in wild-type UV-irradiated
skin treated with both short-term and the long-term UVB
protocols and in tumors of wild-type mice compared with
Ptk6 − /− mice (Figure 3). STAT3 activation is positively
regulated by tyrosine phosphorylation of tyrosine residue 705,
a target of PTK6 (Liu et al., 2006). Several studies have
demonstrated roles for STAT3 in skin tumorigenesis (reviewed
in (Sano et al., 2008; Macias et al., 2013). STAT3-null mice
were resistant to tumorigenesis induced by a 7,12-dimethyl-
benz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate
protocol (Chan et al., 2004). Consistently, disruption of STAT3
impaired and overexpression of STAT3 promoted UVB-
induced skin carcinogenesis in mouse models (Kim et al.,
2009).
Interestingly, membrane association of active PTK6 in
established tumors did not correlate with proliferation
(Figure 4c), and we were unable to detect signiﬁcant
differences in proliferation in the skin between wild-type
and Ptk6− /− mice at any of the time points examined. In
previous studies, we also found no correlation between PTK6
activation and proliferation in established mouse tumors in
the prostate (Zheng et al., 2013b) or mammary gland (Peng
et al., personal communication). However, induction of PTK6
in the mammary glands of Ptk6+/+ ERBB2-overexpressing
mice before tumor formation or signiﬁcant hyperplasia
correlated with increased epithelial cell proliferation and
STAT3 activation compared with the Ptk6− /− mammary
gland (Peng et al., personal communication). Lack of PTK6-
mediated activation of STAT3 could at least in part explain
our ﬁnding that disruption of PTK6 impairs UVB-induced
tumorigenesis in the mouse.
Reduced tyrosine phosphorylation of the PTK6 substrates
FAK (Zheng et al., 2013a) and BCAR1 (Zheng et al., 2012)
was detected in Ptk6− /− mice compared with wild-type
controls (Figure 5). Although BCAR1 is a substrate of FAK,
PTK6 can directly phosphorylate both of these proteins
(Zheng and Tyner, 2013). Both FAK and BCAR1 function in
regulating cell adhesion, migration, and the cell cycle
(reviewed in Barrett et al., 2013; Duperret and Ridky, 2013;
Sulzmaier et al., 2014). Disruption of FAK in keratinocytes led
to some proliferation defects and a thinner epidermis
(Essayem et al., 2006). FAK can regulate SCC cell survival
(Zhang et al., 2004) and has been shown to have roles in
cutaneous cancer stem cells (Schober and Fuchs, 2011).
BCAR1 has an important role in several oncogenic signaling
pathways including the ERBB2 pathway (Cabodi et al., 2006;
Cabodi et al., 2010).
Although an intact Ptk6 gene enhanced UVB-induced
tumorigenesis in SENCAR mice, our analysis of microarray
data of mRNA expression in human SCCs (Lambert et al.,
2014) suggested that PTK6 mRNA expression levels decrease
in less differentiated human cutaneous tumors. This correlates
with the expression pattern observed in normal mouse and
human skin, where PTK6 is expressed in the differentiated
nondividing layers of the epidermis. A number of studies
suggest that PTK6 has context-speciﬁc functions, and its roles
differ depending on cell type/tissue, activation, and intracel-
lular localization (Derry et al., 2003; Brauer et al., 2010;
Zheng and Tyner, 2013; Peng et al., 2014). Activation of PTK6
at the plasma membrane, as reported here in mouse and
human skin tumors, may be a primary requirement for its
tumor-promoting functions. Understanding the signiﬁcance of
changes in the intracellular localization and activation of
PTK6 will be critical for determining when PTK6 may be an
effective therapeutic target in cancer.
MATERIALS AND METHODS
Mouse experiments
SENCAR mice were generated by crossing Charles River (Portage, MI)
CD1 mice with skin tumor–sensitive mice, and they are hypersensi-
tive to UVR (Strickland, 1982; Strickland and Swartz, 1987). This
strain has previously been used as a source of primary keratinocytes
for the study of activation of PTK6 (Vasioukhin and Tyner, 1997) and
other tyrosine kinases (Calautti et al., 1995). The Ptk6-null mouse
model (B6.129SV-Ptk6tm1Aty) in C57BL/6 was backcrossed for over
10 generations to generate a SENCAR Ptk6− /− mouse model. Age-
and sex-matched mice were used for all experiments. All mouse
experiments were reviewed and approved by the University of
Illinois at Chicago Animal Care Committee.
For UVB treatment, the backs of 8-week-old male adult mice were
shaved 24 hours before treatment. Mice were irradiated using an FB-
UVXL-1000 UV crosslinker (Spectroline, Westbury, NY) ﬁtted with
ﬁve 8-Watt 312 nm tubes (Spectronics BLE-8T312, with ﬁlter
assembly). The dorsal epidermis was exposed to 220mJ cm− 2 UVB
irradiation three times per week for weeks 1–6, 260mJ cm− 2 UVB for
weeks 7–8, 300mJ cm− 2 UVB for weeks 9–10, 360mJ cm−2 UVB
for weeks 11–12, 405mJ cm−2 UVB for weeks 13–14, and 450
mJ cm−2 UVB for weeks 15–30. To achieve 220–450mJ cm−2 UVB
irradiation, mice were irradiated for 3–6.5 minutes. UVB irradiation
was stopped at 30 weeks, and mice were kept without further
treatment for 43 weeks. Control animals were regularly shaved but
not exposed to UVB. Mice were photographed and weighed before
each UV treatment. Short-term UVB treatments consisted of 5 doses
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of 220mJ cm− 2 UVB 5 times over the course of 10 days. The mice
were killed after 43 weeks and their skin harvested. The mice were
injected intraperitoneally with BrdU (100 μg per g body weight)
in phosphate-buffered saline 2 hours before killing to measure
proliferation.
Antibodies
Anti-mouse PTK6 (C17), FAK (C20), and Cytokeratin 14 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies against STAT3, P-STAT3 (Y705), P-FAK (Y576,Y577),
P-BCAR1 (Y165), and GAPDH (14C10) were purchased from Cell
Signaling Technology (Danvers, MA). The anti-BCAR1 antibody
came from BD Pharmingen (San Jose, CA). The P-PTK6 (Y342)
antibody came from Millipore. Cytokeratin 10 antibody was
purchased from Abcam (Cambridge, MA). Donkey anti-rabbit and
sheep anti-mouse antibodies conjugated to horseradish peroxidase
were used as secondary antibodies for immunoblotting (Amersham
Biosciences, Pittsburgh, PA) and were detected by chemilumines-
cence using SuperSignal West Dura extended duration substrate
(Pierce, Grand Island, NY).
Protein lysates
Skin tissue was homogenized in 1% Triton X-100 lysis buffer (1%
Triton X-100, 20 mM HEPES, pH 7.4, 150mM NaCl, 1 mM EDTA,
1mM EGTA, 10mM sodium pyrophosphate, 100mM NaF, 5 mM
iodoacetic acid, 0.2 mM phenylmethylsulfonyl ﬂuoride, and protease
inhibitor mixture (Roche Applied Science, Indianapolis, IN). Samples
were separated by SDS-PAGE and transferred to Immobilon-P
membrane (Millipore) for immunoblotting.
Histology and immunoﬂuorescence
Skin tissue was harvested and ﬁxed in 10% neutral-buffered formalin,
embedded in parafﬁn blocks, and cut into 5 μm sections. The slides
were stained with hematoxylin and eosin before histopathologic
examination. For immunoﬂuorescence microscopy, the slides were
deparafﬁnized by xylenes, dehydrated with ethanol, and rehydrated
in phosphate-buffered saline. Antigen retrieval was performed by
incubation in 0.01 M citrate buffer (pH 6.0) at 75 °C for 20minutes.
Sections were blocked in TNT for 30minutes at room temperature.
The primary antibody was incubated overnight at 4 °C in blocking
buffer and washed in TNT, followed by secondary incubation with
biotinylated anti-rabbit or anti-mouse secondary antibodies at room
temperature for 30minutes. Sections were then stained with FITC-
conjugated avidin (Vector Laboratories, Burlingame, CA). For double
staining, FITC-conjugated anti-mouse secondary antibodies (Sigma-
Aldrich, St. Louis, MO) were used to detect primary antibodies made
in mouse (green), and biotinylated anti-rabbit secondary antibodies
(Vector Laboratories) were used and then incubated with Alexa Fluor
594 strepavidin conjugate (Life Technologies, Grand Island, NY) to
detect primary antibodies made in rabbit (red). Slides were mounted
in Vectashield ﬂuorescent mounting medium containing 4’,6-
diamidino-2-phenylindole (Vector Laboratories). The skin was then
viewed using standard UV, rhodamine, or FITC ﬁlters under × 20 and
×40 differential interference contrast objectives using a Zeiss LSM 5
PASCAL confocal microscope. Images were taken using an Axiocam
HRc color digital camera and LSM 5 PASCAL software (Zeiss, Jena,
Germany).
Human tissues
Human tissue sections diagnosed as SCCs were obtained from the
tissue bank in the Section of Dermatology (Department of Medicine,
University of Chicago, Chicago, IL), and their use was approved by
the University of Chicago Institutional Review Board. Slides were
stained with hematoxylin and eosin, total PTK6 (G6 antibody), and
PY342PTK6 antibodies.
Statistical analyses
Quantitative analysis of immunoblot data was performed using
the NIH (Bethesda, MD) ImageJ program (Rasband, 2011). For all
statistical studies, P-values were determined using the two-tailed
Student t-test (Microsoft Excel 2011). Statistical signiﬁcance was
determined by a P-valueo0.05.
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